Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 12/20 | 0.56 |
| ▸ | TTPA | P49638 | 4/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16282036 | 0.81 | PSEN1 (0.57) | PSEN1TTPAALOX5PTGS1PTGS2 | |
| SCHEMBL8380309 | 0.79 | TTPA (0.69) | PSEN1TTPAALOX5PTGS1PTGS2 | |
| SCHEMBL2393197 | 0.78 | PTGS1 (0.68) | PSEN1TTPAALOX5PTGS1PTGS2 | |
| SCHEMBL30951067 | 0.78 | PTGS1 (0.68) | PSEN1TTPAALOX5PTGS1PTGS2 | |
| SCHEMBL15150902 | 0.77 | PSEN1 (0.51) | PSEN1TTPAALOX5PTGS1PTGS2 | |
| SCHEMBL15150890 | 0.77 | TTPA (0.52) | PSEN1TTPAALOX5PTGS1PTGS2 | |
| SCHEMBL30951065 | 0.72 | PTGS1 (0.64) | PSEN1TTPAALOX5PTGS1PTGS2 | |
| SCHEMBL29242846 | 0.72 | PTGS1 (0.64) | PSEN1TTPAALOX5PTGS1PTGS2 | |
| SCHEMBL15150900 | 0.72 | PSEN1 (0.47) | PSEN1TTPAALOX5PTGS1PTGS2 | |
| SCHEMBL14948954 | 0.70 | PSEN1 (0.67) | PSEN1TTPAALOX5PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE42700-E1 | Induction of apoptosis in cancer cells | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-09-13 | — | — | US | disclosed |
| US-7053071-B2 | For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells | THE BURNHAM INSTITUTE (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1456165-A1 | INDUCTION OF APOPTOSIS IN CANCER CELLS | The Burnham Institute (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030176506-A1 | Induction of apoptosis in cancer cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2003-09-18 | — | — | US | disclosed |
| WO-2003048101-A1 | INDUCTION OF APOPTOSIS IN CANCER CELLS | THE BURNHAM INSTITUTE (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176506-A1 | Induction of apoptosis in cancer cells | MCL1, BAD, BCL2 | PSEN1 2827/4885TTPA 1603/4885ALOX5 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.